Results 151 to 160 of about 35,714,339 (381)

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

The Treatment of Leprosy

open access: yesLeprosy Review, 1934
NO CENTURY in the history of medicine has seen such revolutionary changes in our conception of disease, especially in the realm of treatment, as has the twentieth century, particularly in the last 30 years. New discoveries have given rise to fresh approaches to diseases which hitherto were considered incurable, and many of these diseased conditions ...
openaire   +2 more sources

Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda [PDF]

open access: gold, 2009
Barbara Amuron   +7 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Serum Krebs von den Lungen-6 as a potential biomarker for early diagnosis of silicosis: a case-control study

open access: yesBMC Pulmonary Medicine
Background Silicosis is an irreversible and progressive pulmonary fibrosis that results in prolonged inhalation of crystalline silica. Despite its significant impact, no specific blood biomarkers currently exist for the early diagnosis of this disease ...
Qiying Nong   +16 more
doaj   +1 more source

TREATMENT [PDF]

open access: yesBritish Journal of Ophthalmology, 1946
openaire   +2 more sources

Photodynamic therapy in cancer treatment - an update review

open access: diamond, 2019
Ancély Ferreira dos Santos   +4 more
openalex   +2 more sources

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management [PDF]

open access: gold, 2020
Kazuki Sawamoto   +6 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

open access: yesMolecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy